Agaritaban API Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
发布时间:2022-09-07
【概要描述】
Recently, agagatran, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, has been approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed dosage forms.
Recently, agadipiride, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed dosage forms.
According to available information, argatroban is a next-generation anticoagulant belonging to the class of small-molecule direct thrombin inhibitors. Its formulations are primarily used in clinical practice for the treatment of peripheral arterial occlusive disease and for the prevention or management of arterial thrombosis.
Focusing on a business development strategy centered on “active pharmaceutical ingredients plus finished dosage forms,” Shijiazhuang No.4 Pharmaceutical Group has vigorously pursued initiatives to extend, supplement, and strengthen the industrial value chain, achieving significant progress in the R&D of specialty formulations and APIs. Since the beginning of this year, the company has obtained a total of 26 product approvals, including 16 finished dosage form varieties and 10 API varieties, with four of the finished dosage form varieties being the first ever approved by a domestic pharmaceutical enterprise.
Keywords:
Recommended News
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091